A solutions portfolio approach in peritoneal dialysis

Kidney International, Supplement

Volumn 64, Issue 88, 2003, Pages

  Vardhan, Anand ^b   Zweers, Machteld M ^b   Gokal, Ram ^b   Krediet, Raymond T ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b NONE

Author keywords

AGE; Mesothelium; Peritonitis; Ultrafiltration

Indexed keywords

AMINO ACID; BUFFER; DIALYSIS FLUID; GLUCOSE; GLUCOSE DEGRADATION PRODUCT; ICODEXTRIN; LACTIC ACID; MANNITOL; BIOMATERIAL; GLUCAN;

CELL PH; CYTOPATHOGENIC EFFECT; EXCIPIENT COMPATIBILITY; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HUMAN; HYPEROSMOLALITY; MALNUTRITION; METABOLIC ACIDOSIS; NAUSEA; NITROGEN BALANCE; PERITONEAL DIALYSIS; PH MEASUREMENT; PRIORITY JOURNAL; REVIEW; VOMITING; CHEMISTRY; METABOLISM; OSMOLARITY; PH;

AMINO ACIDS; BIOCOMPATIBLE MATERIALS; BUFFERS; DIALYSIS SOLUTIONS; GLUCANS; GLUCOSE; HUMANS; HYDROGEN-ION CONCENTRATION; LACTIC ACID; OSMOLAR CONCENTRATION; PERITONEAL DIALYSIS;

EID: 0344874192     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.08813.x     Document Type: Review

References (104)

1. HEIMBÜRGER O, WANIEWSKI J, WERYNSKI A. et al: Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 38:495-506, 1990
2. DOBBIE JW: Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis. Perit Dial Int 12:14-27, 1992
3. WILLIAMS JD, CRAIG KJ, TOPLEY N, et al: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13:470-479, 2002
4. MATEIJSEN MAM, VAN DER WAL AC, HENDRIKS PMEM, et al: Vascular and interstitial changes in the peritoneum of CAPD patients with peritoneal sclerosis. Perit Dial Int 19:517-525, 1999
5. HONDA K, NITTA K, HORITA H, et al: Morphological changes in the peritoneal vasculature of patients on CAPD with ultrafiltration failure. Nephron 72:171-176, 1996
6. GOTLOIB L, BAR-SELLA P, SHOSTAK A: Reduplicated basal lamina of small venules and mesothelium of human parietal peritoneum. Perit Dial Bull 5: 212-215, 1985
7. DIPAOLO N, SACCHI G: Peritoneal vascular changes in continuous ambulatory peritoneal dialysis (CAPD): An in vivo model for the study of diabetic microangioopathy. Perit Dial Int 9:41-45, 1989
8. DOBBIE JW, ANDERSON JD, HIND C: Long-term effects of peritoneal dialysis on peritoneal morphology. Perit Dial Int 14(Suppl 3):S16-S20, 1994
9. YAMADA K, MIYAHARA Y, HAMAGUCHI K, et al: Immunohistochemical study of human advanced glycosylation end-products (AGE) in chronic renal failure. Clin Nephrol 42:354-361, 1994
10. NAKAYAMA M, KAWAGUCHI Y, YAMADA K, et al: Immunohistochemical detection of advanced glycosylation end-products in the peritoneum and its possible pathophysiological role in CAPD. Kidney Int 51:182-186, 1997
11. DAVIES SJ, BRYAN J, PHILIPS L, RUSSEL GI: Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 11:498-506, 1996
12. ZWEERS MM, SPLINT LJ, KREDIET RT, STRUIJK DG: Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant 16:651-654, 2001
13. HENDRIKS PMEM, HO-DAC-PANNEKEET MM, VAN GULIK TM, et al: Peritoneal sclerosis in chronic peritoneal dialysis patients: Analysis of clinical presentation, risks factor and peritoneal transport characteristics. Perit Dial Int 17:136-143, 1997
14. DAVIES SJ, PHILLIPS L, NAISH PF, RUSSEL GI: Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 12:1046-1051, 2001
15. TOPLEY N, COLES GA, WILLIAMS JD: Biocompatibility studies on peritoneal cells. Perit Dial Int 14(Suppl 3):S21-S28, 1994
16. PEDERSEN FB, RYTTOV N, DELEURAN P, et al: Acetate versus lactate in peritoneal dialysis solutions. Nephron 39:55-58, 1985
17. MAHIOUT A, BRUNKHORST R: Pyruvate anions neutralize peritoneal dialysate toxicity. Nephrol Dial Transplant 10:391-394, 1995
18. SHOSTAK A, GOTLOIB L, KUSHNIER R, WAJSBROT V: Protective effect of pyruvate upon cultured mesothelial cells exposed to 2 mM hydrogen peroxide. Nephron 4:362-366, 2000
19. BEYER-MEARS A, DIECKE FP, MISTRY K, et al: Effect of pyruvate on lens myo-inositol transport and polyol formation in diabetic cataract. Pharmacology 55:78-86, 1997
20. WONG TYH, PHILIPS AO, WITOWSKI J, TOPLEY N: Glucose-mediated induction of TGF-β and MCP-1 in mesothelial cells in vitro is osmolality and polyol pathway dependent. Kidney Int, in press
21. BREBOROWICZ A, RODELA H, OREOPOULOS DG: Toxicity of osmotic solutes on human mesothelial cells in vitro. Kidney Int 41:1280-1285, 1992
22. GOTLOIB L, WAISBRUT V, SHOSTAK A, KUSHNIER R: Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose enriched, lactate buffered dialysis solution. Nephron 70:466-477, 1995
23. KUMANO K, SCHILLER B, HJELLE JT, et al: Effect of osmotic solutes on fibronectin mRNA expression in rat peritoneal mesothelial cells. Blood Purif 14:165-169, 1996
24. ZWEERS MM, DE WAART DR, SMIT W, et al: Growth factors VEGF and TGF-β1 in peritoneal dialysis. J Lab Clin Med 134:124-132, 1999
25. ZWEERS MM, STRUIJK DG, SMIT W, KREDIET RT: Vascular endothelial growth factor in peritoneal dialysis. A longitudinal follow-up. J Lab Clin Med 137:125-132, 2001
26. HONDA K, NITTA K, HORITA S, et al: Accumulation of advanced glycation end-products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with ultrafiltration failure. Nephrol Dial Transplant 14:1541-1549, 1999
27. FRIEDLANDER MA, Wu Y-C, SCHALAK JA, et al: Influence of dialysis modality on plasma and tissue concentrations of pentosidine in patients with end-stage renal disease. Am J Kidney Dis 25:445-451, 1995
28. DEGENHARDT TP, GRASS L, REDDY S, et al: The serum concentration of the advanced glycation end-products in N-(carboxymethyl)lysine is increased in uremia. Kidney Int 52:1064-1067, 1997
29. MIYATA T, VAN YPERSELE-DE STRIHOU C, KUROKAWA G, BAYNES JN: Alterations in non-enzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55:389-399, 1999
30. MIYATA T, KEDA Y, YAMADA Y, et al: Accumulation of carbonyl accelerates the formation of pentosidine, in advanced glycation end-products: Carbonyl stress in uremia. J Am Soc Nephrol 9:2349-2356, 1998
31. WEISS MF, ERHARD P, KADER-ATTIA FA, et al: Mechanisms for the formation of glyoxidation products in end-stage renal disease. Kidney Int 57:2571-2585, 2000
32. MIYATA T, ISHIKAWA S, ASAKI K, et al: 2-Isopropylidenehydroazo-4-oxo- thiazolin-5-ylacetanilide-(OPB-9195) treatment inhibits the development of intimal thickening after balloon injury of rat carotics artery: Role of glyoxidation and lipoxidation reactions in vascular tissue damage. FEBS Letters 445:202-206, 1999
33. FRIEDLANDER MA, WITKO-SARSAT V, NGAYEN AT, et al: The advanced glycation end-product pentosidine and monocyte activation in uremia. Clin Nephrol 45:379-382, 1996
34. AMORE A, CIRINA P, MITOLA S, et al: Non-enzymatically glycated albumin (Amadori adducts) enhances nitric oxyde synthase activity and gene expression in endothelial cells. Kidney Int 51:27-35. 1997
35. HO-DAC-PANNEKEET MM, WEISS MF, DE WAART DR, et al: Analysis of non-enzymatic glycosylation in vivo: Impact of different dialysis solutions. Perit Dial Int 19(Suppl 2):S68-S74, 1999
36. WIESLANDER AP, NORDIA MK, KJELLSTRAND PTT, BOBERG UC: Toxicity of peritoneal dialysis fluids on cultured fibroblasts, L-929. Kidney Int 40:77-79, 1991
37. LINDEN T, COHEN A, DEPPISCH R, et al: 3,4-Dideoxyglucosone-3-ene (3,4-DGE): A cytoxic glucose degradation product in fluids for peritoneal dialysis. Kidney Int 62:697-703, 2002
38. WITOWSKI J, KORYBALSKA K, WISNIEWSKA J, et al: Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol 11:729-739, 2000
39. INAGI R, MIYATA T, YAMAMOTO T, et al: Glucose degradation product methylglyoxal enhances the production of vascular endothelial growth factor in peritoneal cells: A role in the functional and morphological alterations of peritoneal membrane in peritoneal dialysis. FEBS Letters 463:260-264, 1999
40. MIYATA T, HORIE K, UEDA Y, et al: Advanced glycation and lipidoxidation of the peritoneal membrane: Respective roles of serum and peritoneal fluid reactive carbonyl compounds. Kidney Int 58:425-435, 2000
41. ZEIER M, SCHWENGER V, DEPPISCH R, et al: Glucose degradation products in PD fluids: Do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 63:248-305, 2003
42. Ho T, YORIOKA N, YAMAMOTO M, et al: Effect of glucose on intercellular junction of cultured human peritoneal mesothelial cells. J Am Soc Nephrol 11:1969-1979, 2000
43. SITTER T, HASLINGER B, MANDL S, et al: High glucose increases prostaglandin E2 synthesis in human peritoneal mesothelial cells: Role of hyperosmolarity. J Am Soc Nephrol 9:2005-2012, 1998
44. SITTERT, MANDL-WEBERS, WORNLE M. et al: D-Glucose increases the synthesis of tissue-type plaminogen activator (t-PA) in human peritoneal mesothelial cells. Thromb Haemost 82:1171-1176, 1999
45. KANG DH, HONG YS, LIM HJ, et al: High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor β1 of human peritoneal mesothelial cells: Effect of cytokine costimulation. Perit Dial Int 19:221-230, 1999
46. Hu H, Yu MR, LEE HB: High glucose-induced PKL activation medicates TGF-β1 and fibronectin synthesis by peritoneal mesothelial cells. Kidney Int 59:463-470, 2001
47. ROUGIER J-P, MOULLIER P, PIEDAGNEL R, et al: Hyperosmolality suppresses, but TGF-β1 increases MMP 9 in human peritoneal mesothelial cells. Kidney Int 51:337-347, 1997
48. LIEBEREK T, TOPLEY N, JÖRRES A, et al: Peritoneal dialysis fluid inhibition of phagocytic fucntion: Effects of osmolality and glucose concentration. J Am Soc Nephrol 3:1508-1515, 1993
49. GOTLOIB L, WAJSHBROT V, SHOSTAK A, KUSHNIER R: Effects of hyperosmolarity upon the mesothelial monolayer exposed in vivo and in situ to a mannitol-enriched dialysis solution. Nephron 81:305-309, 1999
50. HO-DAC-PANNEKEET MM, SCHOUTEN N, LANGEDIJK MJ, et al: Peritoneal transport characteristics with glucose polymer based dialysate. Kidney Int 50:979-986, 1996
51. LIBEREK T, TOPLEY N, MISTRY CD, et al: Cell function and viability in glucose polymer peritoneal dialysis fluid. Perit Dial Int 13:104-111, 1993
52. JÖRRES A, GAHL GM, TOPLEY N, et al: In vitro biocompatibility of alternative CAPD fluids: Comparison of bicarbonate buffered and glucose polymer based solutions. Nephrol Dial Transplant 9:785-790, 1994
53. THOMAS S, SCHENK U, and FISCHER F, et al: In vitro effects of glucose polymer-containing peritoneal dialysis fluids on phagocytic activity. Am J Kidney Dis 29:246-253, 1997
54. DE FIJTER CWH, VERBRUGH HA, OE LP, et al: Biocompatibility of a glucose polymer-containing peritoneal dialysis fluid. Am J Kidney Dis 4:411-418, 1993
55. BAJO MA, SELGAS R, CASTRO MA, et al: Icodextrin effluent leads to a greater proliferation than glucose effluent of human mesothelial cells studies ex vivo. Perit Dial Int 20:742-747, 2000
56. MISTRY CD, GOKAL R, PEERS E: A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solution in CAPD. MIDAS Study Group. Multicenter Investigation of Icodextrin in Ambulatory Peritoneal Dialysis. Kidney Int 46:496-503, 1994
57. WOLFSON M, PIRAINO B, HAMBURGER RJ, MORTON AR: A randomized controlled trial to evaluate the efficacy and safety of icodextrin in peritoneal dialysis. Am J Kidney Dis 40:1055-1065, 2002
58. POSTHUMA N, TER WEE PM, VERBRUGH HA, et al: Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 12:550-553, 1997
59. PLUM J, GENTILE S, VERGER C, et al: Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis. 39:862-871, 2002
60. ARAUJO MRT, RAMAO JE, SABBAGA E, et al: The relationship between ultrafiltrate volume with icodextrin and peritoneal transport pattern according to the peritoneal equilibration test. Perit Dial Int 22:229-233, 2002
61. IMHOLZ ACT, BROWN CB, KOOMEN GCM, et al: The effect of glucose polymers on water removal and protein clearances during CAPD. Adv Perit Dial 9:25-30, 1993
62. PEERS EM, SCRIMGEOUR AC, HAYCOX AR: Cost-containment in CAPD patients with ultrafiltration failure. Clin Drug Invest 10:53-58, 1995
63. WILKIE ME, PLANT MJ, EDWARDS L, BROWN CB: Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: Extension of CAPD technique survival. Perit Dial Int 17:84-97, 1997
64. JOHNSON DW, ARNDT M, O'SHEA A, et al: Icodextrin as salvage therapy in peritoneal dialysis patients with refractory fluid overload. BMC Nephrol 2:2, 2001
65. KREDIET RT, ZUYDERHOUDT FM, BOESCHOTEN EW, ARISZ L: Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 17:43-52, 1987
66. DOUMA CE, DE WAART DR, STRUIJK DG, KREDIET RT: Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis? J Lab Clin Med 132:329-340, 1998
67. PANNEKEET MM, IMHOLZ AL, STRUIJK DG, et al: The standard peritoneal permeability analysis: A tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 48:866-875, 1995
68. CARLSSON O, RIPPE B: Peritoneal lymphatic absorption and solute exchange during zymosan-induced peritonitis in the rat. Am J Physiol 277:H1107-H1112, 1999
69. GOKAL R, MISTRY CD, PEERS EM: Peritonitis occurrence in a multicentre study of icodextrin and glucose in CAPD. MIDAS Study Group. Multicentre Investigation of Icodextrin in Ambulatory Dialysis. Perit Dial Int 15:226-230, 1995
70. POSTHUMA N, TER WEE PM, DONKER, et al: Icodextrin use in CCPD patients during peritonitis: Ultrafiltration and serum disaccharide concentrations. Nephrol Dial Transplant 13:2341-2344, 1998
71. POSTHUMA N, TER WEE PM, DONKER, et al: Assessment of the effectiveness, safety, and biocompatibility of icodextrin in automated peritoneal dialysis. The Dextrin in APD in Amsterdam (DIANA) Group. Perit Dial Int 20(Suppl 2):S106-S113, 2000
72. 2-microglobulin in contiunous ambulatory peritoneal dialysis: Influence of renal and enhanced peritoneal clearances using glucose polymer. Nephrol Dial Transplant 5:513-519, 1990
73. KREDIET RT, BROWN CB, IMHOLZ ALT, KOOMEN GCM: Protein clearance and icodextrin. Perit Dial Int 14(Suppl 2):S39-S44, 1994
74. DELARUE J, MAINGOURD C, LAMISSE F, et al: Glucose oxidation after a peritoneal and an oral glucose load in dialyzed patients. Kidney Int 45:1147-1152, 1994
75. WOODROW G, OLDROYD B, STABLES G, et al: Effects of icodextrin in automated peritoneal dialysis on blood pressure and biolelectrical impedance analysis. Nephrol Dial Transplant 15:862-866, 2000
76. KONINGS CJ, KOOMAN JP, SCHONCK M, et al: Fluid status in CAPD patients is related to peritoneal transport and residual renal function: Evidence from a longitudinal study. Nephrol Dial Transplant 18:797-803, 2003
77. KONINGS CJ, KOOMAN JP, SCHONCK M, et al: Effect of icodextrin on volume status, blood pressure and echocardiographic parameters: A randomized study. Kidney Int 63:1556-1563, 2003
78. BROWN EA, DAVIES SJ, HEIMBURGER O, et al: Adequacy targets can be met in anuric patients by automated peritoneal dialysis: Baseline data from EAPOS. Perit Dial Int 21(Suppl 3):S133-S137, 2001
79. OYIBO SO, PRITCHARD GM, MCLAY L. et al: Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease. Diabet Med 19:693-696, 2002
80. WENS R, TAMINNE M, DEVRIENDT J, et al: A previously undescribed side effect of icodextrin: Overestimation of glycemia by glucose analyzer. Perit Dial Int 18:603-609, 1998
81. SCHOENICKE G, GRABENSEE B, PLUM J: Dialysis with icodextrin interferes with measurement of serum alpha-amylase activity. Nephrol Dial Transplant 17:1988-1992, 2002
82. BRULEZ HFH, HEEZIUS ECJM, DE FIJTER CWJ, et al: In vitro compatibility of a 1.1% aminoacid containing peritoneal dialysis fluid with phagocyte function. Adv Perit Dial 10:241-244, 1994
83. BRULEZ HFH, DEKKER HA TH, OE PL, et al: Biocompatibility of a 1.1% aminoacid containing peritoneal dialysis (PD) fluid compared to a 2.27% glucose-based PD-fluid. Nephron 74:26-32, 1996
84. DOUMA CE, DE WAART DR, STRUIJK DG, KREDIET RT: Effect of amino acid based dialysate on peritoneal blood flow and permeability in stable CAPD patients: A potential role for nitric oxide? Clin Nephrol 45:295-302, 1996
85. JONES MR, GEHR TW, BURKART JM. et al: Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution. Perit Dial Int 18:210-216, 1998
86. KOPPLE JD, BERNARD D, MESSANA J, et al: Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 47:1148-1157, 1995
87. DELARUE J, MAINGOURD C, OBJOIS M, et al: Effects of an amino acid dialysate on leucine metobolism in continuous ambulatory peritoneal dialysis patients. Kidney Int 56:1934-1943, 1999
88. FALLER B, APARICIO M, FAICT D, et al: Clinical evaluation of an optimized 1.1% amino acid solution for peritoneal dialysis. Nephrol Dial Transplant 10:1432-1437, 1995
89. COOKER CA, LUNEBURG P, FAICT D, et al: Reduced glucose degradation products in bicarbonate/lactate-buffered peritoneal dialysis solutions produced in two-chambered bags. Perit Dial Int 17:373-378, 1997
90. SCHAMBYE HT, PEDERSON FB, WANG P: Bicarbonate is not the ultimate answer to the biocompatibility problems of CAPD solutions: A cytotoxicity test of CAPD solutions and effluents. Adv Perit Dial 8:42-46, 1992
91. SCHAMBYE HT: Effects of different buffers on the biocompatibility of CAPD solutions. Perit Dial Int 16(Suppl 1):S130-S136, 1996
92. TOPLEY N, KAUR D, PETERSEN MM, et al: In vitro effects of bicarbonate and bicarbonate/lactate-buffered peritoneal dialysis solutions on mesothelial and neutrophil function. J Am Soc Nephrol 7:218-224, 1996
93. MACKENZIE RK, HOLMER CJ, MOSELEY A, et al: Bicarbonate/ lactate-and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophase TNFα secretion. J Am Soc Nephrol 9:1499-1506, 1998
94. HEKKING LHP, ZAREIE M, DRIESPRONG BAJ, et al: Better preservation of peritoneal morphologic features and defence in rats after long-term exposure to a bicarbonate/lactate-buffered solution. J Am Soc Nephrol 12:1775-2786, 2001
95. COLES GA, GOKAL R, OGG C. et al: A randomized controlled trial of a bicarbonate-and a bicarbonate/lactate-containing dialysis solution in CAPD. Perit Dial Int 17:48-51, 1997
96. COLES GA, O'DONOGHUE, DJ, PRITCHARD N, et al: A controlled trial of two bicarbonate-containing dialysis fluids for CAPD - Final report. Nephrol Dial Transplant 13:3165-3171, 1998
97. MACTIER RA, SPROSEN TS, GOKAL R, et al: Bicarbonate and bicarbonate/lactate PD solutions for the treatment of infusion pain. Kidney Int 53:1061-1067, 1998
98. TRANAEUS A, for the Bicarbonate/lactate Study Group: A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution - Clinical benefits. Perit Dial Int 20:516-523, 2000
99. OTTE K, GONZALEZ T, BAJO M-A, et al: Clinical experience with a new bicarbonate (25 mmol/L)/lactate (10 mmol/L) peritoneal dialysis solution. Perit Dial Int 23:138-145, 2003
100. JONES S, HOLMES CJ, KREDIET RT, et al: Bicarbonate/lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyalyronic acid levels. Kidney Int 59:1529-1538, 2001
101. KREDIET RT: Dialysate cancer antigen 125 concentration as a marker of peritoneal membrane status in patients treated with chronic peritoneal dialysis. Perit Dial Int 21: 560-567, 2001
102. HO-DAC-PANNEKEET MM, KREDIET RT: Inflammatory changes in vivo during CAPD: What can the effluent tell us? Kidney Int 50(Suppl 56):S12-S16, 1996
103. RIPPE B, SIMONSEN O, HEIMBÜRGER O, et al: Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products. Kidney Int 59:348-357, 2001
104. DEVUYST O, TOPLEY N, WILLIAMS JD: Morphological and functional changes in the dialysed peritoneal cavity: Impact of more biocompatible solutions. Nephrol Dial Transplant 17(Suppl 3):12-15, 2002